论文部分内容阅读
目的 应用保尔佳治疗晚期恶性肿瘤 ,以观察其临床疗效。方法 应用保尔佳 +常规化疗作为治疗组85例 ,单纯用化疗 5 1例作为对照组。所有病例均采用肌肉注射和投药器给药 ,每天 1～ 2支。其中乳腺癌 32例 ;胃癌2 9例 ;大肠癌 12例 ;肝癌 5例 ;其它癌 7例。所有病例均有病理诊断及可观察指标。通过X片、B超、CT等客观指标观察其病灶变化、免疫指标提高情况以及白细胞升降情况。结果 在实体瘤观察中治疗组治疗后总缓解率 (CR +PR)为 18.8% (16例 ) ;好转率 (MR)为 16 .5 % (14例 )。而对照组中以上两项分别为 3 .9%及 11.8%。具有显著性差异 (P<0 .0 1)。在免疫指标及白细胞方面的观察亦有明显差异 (P <0 .0 1及 0 .0 5 )。结论 保尔佳具有抗癌抑癌作用 ,使机体免疫力提高并且具有升高白细胞及止疼作用 ,对肿瘤病人生存期有一定的提高。
Objective To evaluate the clinical efficacy of Pallier in the treatment of advanced malignant tumors. Methods Baerjia + routine chemotherapy as the treatment group 85 cases, simple chemotherapy with 51 cases as the control group. All cases were administered intramuscularly and drug administration, 1 to 2 per day. Breast cancer in 32 cases; 29 cases of gastric cancer; 12 cases of colorectal cancer; Liver cancer in 5 cases; 7 cases of other cancers. All cases were pathological diagnosis and observable indicators. Through the X-ray, B-, CT and other objective indicators observed changes in its lesions, immune indicators to improve the situation and leukocyte movements. Results In the observation of solid tumors, the total response rate (CR + PR) of the treatment group after treatment was 18.8% (16 cases), and the improvement rate (MR) was 16.5% (14 cases). In the control group, the above two items were 3.9% and 11.8% respectively. There was significant difference (P <0.01). There were also significant differences in immunological parameters and leukocyte counts (P <0.01 and 0.05). Conclusion Paul good anti-cancer effect with anti-cancer, immune system to improve and have increased leukocyte and analgesic effect on the survival of cancer patients have a certain increase.